產品詳情
查看大圖

  • 產品名稱：CRL-2638 CT26.WT 小鼠結腸癌細胞

  • 產品型號：CRL-2638
  • 產品廠商：其它品牌
  • 產品文檔：
你添加了1件商品 查看購物車
簡單介紹：
簡單介紹 CRL-2638 CT26.WT 小鼠結腸癌細胞，原代細胞|細胞係|細胞株|菌種；細胞庫管理規範，提供的細胞株背景清楚，提供參考文獻和**培養條件！
詳情介紹：

CRL-2638 CT26.WT 小鼠結腸癌細胞 的詳細介紹
CRL-2638 CT26.WT 小鼠結腸癌細胞
ATCC® Number: CRL-2638™    Price:
Designations: CT26.WT
Depositors:  N Restifo
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent
Organism: Mus musculus (mouse)
Morphology: fibroblast
Source: Strain: BALB/c
Organ: colon
Disease: carcinoma
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
 
Tumorigenic: Yes
Antigen Expression: H-2d [53315]
Comments: CT26 is an N-nitroso-N-methylurethane-(NNMU) induced, undifferentiated colon carcinoma cell line. It was cloned to generate the cell line designated CT26.WT (ATCC CRL-2638).
CT26.WT was stably transduced with the retroviral vector LXSN that contains the lacZ gene encoding the model tumor associated antigen (TAA), beta-galactosidase (beta-gal) to obtain the lethal subclone CT26.CL25 (ATCC CRL-2639). [53315]
The growth rate and lethality of CT26.CL25 and CT26.WT is virtually identical despite the expression by CT26.CL25 of the model TAA, beta-galactosidase, in normal mice. [53315]
The cell line can be used with CT26.CL25 (ATCC CRL-2639) as a model for testing immunotherapy protocols and in studies on the host immune response.
A culture submitted to the ATCC in July of 2001 was found to be contaminated with mycoplasma. Progeny were cured by a 21-day treatment with BM Cycline.
The cells were assayed for mycoplasma, by the Hoechst stain, PCR and the standard culture test, after a six-week period following treatment. All tests were negative.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10.
Atmosphere: air, 95; carbon dioxide (CO2), 5
Temperature: 37.0°C
Subculturing: Protocol:
  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25 (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C.

Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:10 is recommended
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium supplemented with 5 (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
derivative:ATCC CRL-2639
References: 53315: Wang M, et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol. 154: 4685-4692, 1995. PubMed: 7722321


滬公網安備 31010902002433號